Physician profile
Gregory Tadduni
NPI 1063452035
$392.76
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.46 · 2020: $53.94 · 2021: $237 · 2022: $70.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $113.02 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $94.34 | 2021-2022 | |
| Depuy Synthes Sales INC. | $79.35 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $35.41 | 2021-2022 | |
| Heron Therapeutics, INC. | $23.20 | 2021 | |
| Orthogenrx INC. | $16.98 | 2020 | |
| Smith+Nephew, INC. | $16.26 | 2019 | |
| Axogen | $14.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Tadduni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.